Ribociclib for HR+/HER2- Advanced Breast Cancer in Postmenopausal Women
Ribociclib 600 mg daily (3 weeks on/1 week off) combined with an aromatase inhibitor (letrozole or anastrozole) is the recommended first-line treatment for postmenopausal women with HR-positive, HER2-negative advanced breast cancer, as this combination significantly improves both progression-free survival (25.3 vs 16.0 months) and overall survival compared to endocrine therapy alone. 1
Dosing Regimen
Standard Dosing:
- 600 mg orally once daily for 21 consecutive days, followed by 7 days off (28-day cycle) 2
- Continue until disease progression or unacceptable toxicity 2
- Administer with food (preferably at the same time each day) 2
Combination Partners:
- First-line: Letrozole 2.5 mg or anastrozole 1 mg daily (continuous) 1, 2
- Second-line (after AI progression): Fulvestrant 500 mg IM (Days 1,15,29, then monthly) 2
Monitoring Requirements
Baseline Assessment:
- Complete blood count (CBC) with differential
- Liver function tests (AST, ALT, bilirubin)
- ECG to assess QTc interval 2
- Electrolytes (potassium, magnesium, calcium) - correct abnormalities before starting 2
During Treatment:
- CBC: Every 14 days for first 2 cycles, then at start of each subsequent cycle 3
- LFTs: Every 2 weeks for first 2 cycles, then at start of each cycle 1
- ECG: Day 14 of Cycle 1, start of Cycle 2, then as clinically indicated 2
Dose Adjustments
For Neutropenia (Primary Toxicity):
- Grade 1-2 (ANC ≥1000/mm³): Continue at current dose
- Grade 3 (ANC 500-999/mm³): Hold ribociclib until recovery to Grade ≤2, then resume at same dose. If recurs, reduce to 400 mg
- Grade 4 (ANC <500/mm³): Hold until recovery to Grade ≤2, reduce to 400 mg. If recurs at 400 mg, reduce to 200 mg 2
For Hepatotoxicity:
- Grade 2 ALT/AST elevation: Hold until recovery to Grade ≤1, resume at reduced dose (400 mg, then 200 mg if recurs)
- Grade 3-4: Hold until recovery to baseline, resume at reduced dose or discontinue based on severity 1
For QTc Prolongation:
- QTcF >480 ms but <500 ms: Hold ribociclib, correct electrolytes, repeat ECG. Resume at reduced dose when QTcF <481 ms
- QTcF ≥500 ms: Discontinue permanently 2
Contraindications and Precautions
Absolute Contraindications:
- Baseline QTcF >450 ms 2
- Concomitant use with strong CYP3A inhibitors or medications that prolong QT interval 2
Use with Caution:
- Hepatic impairment (dose reduction required for moderate-severe) 2
- Cardiac disease or risk factors for QTc prolongation 4
- Elderly patients ≥75 years (increased toxicity risk) 2
Important Drug Interactions:
- Avoid: Strong CYP3A4 inhibitors (ketoconazole, clarithromycin), strong inducers (rifampin, phenytoin), QT-prolonging drugs
- Tamoxifen + ribociclib: Avoid this combination due to increased cardiotoxicity risk 5
Alternative CDK4/6 Inhibitor Options
When ribociclib is not suitable:
Palbociclib 125 mg daily (21/7 schedule):
- Similar efficacy (PFS 24.8 months with letrozole) 1
- Lower rates of hepatotoxicity and QTc prolongation 1
- Preferred in patients with cardiac risk factors or hepatic dysfunction 4
- Primary toxicity: neutropenia (66.5% Grade 3/4) 1
Abemaciclib 150 mg twice daily (continuous):
- Continuous dosing (no week off) 1
- Different toxicity profile: diarrhea (9.5% Grade 3+) more common than neutropenia 1
- Preferred when continuous dosing desired or in patients intolerant to myelosuppression 1
Special Populations
Premenopausal Women:
- Add ovarian suppression with goserelin 3.6 mg SC every 28 days or leuprolide 1
- MONALEESA-7 demonstrated OS benefit (70% vs 46% at 3.5 years, HR 0.71) 1
Men:
- Use with LHRH agonist (goserelin or leuprolide) plus AI 5, 2
- Limited data but FDA-approved based on COMPLEEMENT-1 trial 2
Key Clinical Pearls
- Neutropenia is typically uncomplicated: Febrile neutropenia rates remain low (1-2%) despite high Grade 3/4 neutropenia rates (62%) 1
- Dose reductions maintain efficacy: Real-world data show dose adjustments preserve progression-free survival while improving treatment duration and overall survival 6
- Hepatotoxicity is reversible: LFT elevations (10.2% Grade 3/4) are manageable with dose holds/reductions 1
- Overall survival benefit established: Ribociclib is the only CDK4/6 inhibitor with demonstrated OS improvement in multiple trials 1